Success Metrics

Active Trials
1(17%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_2
3
50%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Terminated(1)
Other(3)

Detailed Status

unknown3
Recruiting1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 23 (50.0%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

unknown350%
recruiting117%
withdrawn117%
not_yet_recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_2

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

NCT07012798
recruitingphase_4

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

NCT05124002
withdrawnphase_2

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

NCT03722498
unknownphase_3

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

NCT03780049
unknownphase_2

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

NCT03812770
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07012798Phase 2

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Not Yet Recruiting
NCT05124002Phase 4

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Recruiting
NCT03722498Phase 2

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Withdrawn
NCT03780049Phase 3

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Unknown
NCT03812770Phase 2

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Unknown
NCT03468231Phase 3

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6